These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29767871)

  • 1. Expression and clinical significance of Ki-67, E-cadherin, and mesothelin in serous borderline ovarian tumor.
    Yu N; Wang N; Liu YF; Li YY; Zhang TG
    Eur J Gynaecol Oncol; 2017; 38(1):85-90. PubMed ID: 29767871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
    Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
    Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
    Cheng JC; Auersperg N; Leung PC
    Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma.
    Kakimoto S; Miyamoto M; Einama T; Matsuura H; Iwahashi H; Ishibashi H; Sakamoto T; Hada T; Takano M
    Pathol Oncol Res; 2020 Oct; 26(4):2299-2306. PubMed ID: 32468249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of mesothelin mRNA and protein in ovarian carcinomas].
    Bi SN; Dai SZ; Yao Q; Che YC; Wang N
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):288-91. PubMed ID: 18788634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases.
    Daraï E; Scoazec JY; Walker-Combrouze F; Mlika-Cabanne N; Feldmann G; Madelenat P; Potet F
    Hum Pathol; 1997 Aug; 28(8):922-8. PubMed ID: 9269828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoexpression of beta-catenin--E-cadherin complex in primary serous ovarian tumors.
    Stawerski P; Wagrowska-Danilewicz M; Stasikowska O; Gottwald L; Danilewicz M
    Pol J Pathol; 2008; 59(1):27-32. PubMed ID: 18655368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Epithelial-Mesenchymal Transition, E-cadherin and Tumor Progression in Ovarian Serous Tumors.
    Bozhkova DM; Poryazova-Markova EG
    Folia Med (Plovdiv); 2019 Jun; 61(2):296-302. PubMed ID: 31301662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rat model of serous borderline ovarian tumors induced by 7,12-dimethylbenz[a]anthracene.
    Cai SQ; Li Y; Li YA; Wang L; Zhu J; Zhao SH; Li X; Qiang JW
    Exp Anim; 2019 Aug; 68(3):257-265. PubMed ID: 30760660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy.
    Hanaoka T; Hasegawa K; Kato T; Sato S; Kurosaki A; Miyara A; Nagao S; Seki H; Yasuda M; Fujiwara K
    Mol Diagn Ther; 2017 Apr; 21(2):187-198. PubMed ID: 28160193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study.
    De Nictolis M; Garbisa S; Lucarini G; Goteri G; Masiero L; Ciavattini A; Garzetti GG; Stetler-Stevenson WG; Fabris G; Biagini G; Prat J
    Int J Gynecol Pathol; 1996 Apr; 15(2):102-9. PubMed ID: 8786198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
    Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
    Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas.
    Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Ferreira VM; Lopes CS
    Hum Pathol; 2004 Jun; 35(6):663-9. PubMed ID: 15188131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors.
    Giurgea LN; Ungureanu C; Mihailovici MS
    Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of serum mesothelin in malignant and benign ovarian masses.
    Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
    Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DNA methylomes of serous borderline tumors reveal subgroups with malignant- or benign-like profiles.
    Zeller C; Dai W; Curry E; Siddiq A; Walley A; Masrour N; Kitsou-Mylona I; Anderson G; Ghaem-Maghami S; Brown R; El-Bahrawy M
    Am J Pathol; 2013 Mar; 182(3):668-77. PubMed ID: 23357500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
    Cai Y; Shao SL; Wang QH; Yan LJ; Wang XY; Wang LX
    Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Ovarian Tumors with Multidetector Computed Tomography and Tumor Markers: Differentiation of Stage I Serous Borderline Tumors and Stage I Serous Malignant Tumors Presenting as Solid-Cystic Mass.
    Yu XP; Liu Y; Jiao JW; Yang HJ; Wang RJ; Zhang S
    Med Sci Monit; 2020 Aug; 26():e924497. PubMed ID: 32801292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.